THE COST‐EFFECTIVENESS OF DOXAZOSIN FOR THE TREATMENT OF HYPERTENSION IN TYPE II DIABETIC PATIENTS IN THE UK AND ITALY

Abstract

SUMMARYThe objective of this analysis was to assess the cost‐effectiveness of achieving ‘tight control’ versus ‘less tight control’ of blood pressure, as defined in the UK Prospective Diabetics Study 38, in type II diabetic patients in the UK and Italy. The effect of including doxazosin in a ‘tight control’ combination therapy was analysed. Given doxazosin's positive impact on lipid levels in addition to its antihypertensive effect, it is hypothesised that treatment including doxazosin will reduce the incidence of macrovascular complications. For each country, a Markov model was constructed to simulate macrovascular outcomes of patients on various drug combinations. Transitional probabilities were based on the risk rates presented in UKPDS 38. Risk rates were adjusted for the ageing of the cohort and the lipid‐lowering properties of doxazosin using Framingham risk equations. Incremental cost‐effectiveness ratios ranged from £2224 to £4867 (US$3225–7057) per life‐year saved for the UK and from L1.8–9.3 million (US$818–4159) per life‐year saved for Italy. Doxazosin is a cost‐effective agent when included in a combination therapy in the treatment of hypertension in the diabetic populations of the UK and Italy.